english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Tramadol: an opioid analgesic to be used with caution

Classified as a weak opioid, tramadol poses risks that require the same vigilance as with morphine.
1 June 2020

Thyroid hormone treatment: no proof of benefit in asymptomatic subclinical hypothyroidism

According to a systematic review of comparative trials in approximately 2 000 patients, symptomless hypothyroidism discovered incidentally does not require thyroid hormone treatment (levothyroxine).
1 June 2020

Measles-mumps-rubella vaccine (MMR): no link with autism

FEATURED REVIEW Studies based on a very significant number of children, taken together, do not show any link between MMR vaccination and the occurrence of autistic disorders. The authors of the two studies claiming the opposite used incorrect data or applied inappropriate analytical methods.
Full review (3 pages) available for download by subscribers.
1 May 2020

In the May issue of Prescrire International: Dulaglutide (Trulicity°) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality

FREE DOWNLOADIn patients with type 2 diabetes who had a modest elevation of HbA1c, a recent trial suggested that addition of dulaglutide to hypoglycaemic therapy slightly reduced the risk of stroke, but did not reduce either all-cause mortality or cardiovascular mortality.
Full text available for free download.
1 May 2020

Rumours that kill

Health care is a field in which rumours flourish: it is not always easy to tell true from false or rumour from robust evidence. Health decisions are safest when based on data that have been extricated from the various forms of bias and influence that can distort information about health care.
1 May 2020

Dry eye: sometimes associated with antimuscarinic drugs

When faced with a patient with dry eye, recognising the possible role of antimuscarinic drugs (also known as atropinics) helps in choosing the best treatment strategy: discontinuing these drugs or possibly replacing them with another drug, reducing the dose or introducing treatment to alleviate the symptoms of dry eye disease.
1 May 2020

Pregabalin (Lyrica° or other brands) and gabapentin (Neurontin° or other brands): known dangers and uncertainties during pregnancy

Taken during pregnancy, pregabalin and gabapentin expose the newborn to harmful effects.
1 May 2020

Cytotoxic drugs: risks for healthcare professionals

Exposure to cytotoxic drugs, which are often genotoxic, carcinogenic or reprotoxic, poses a risk to the health of healthcare and other professionals.
1 May 2020

New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other brands)

 NEWS UPDATE  As of mid-April 2020, more and more clinical data are confirming that the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other brands) carries a risk of serious cardiac adverse effects: prolongation of the QT interval with a high risk of cardiac arrhythmia and torsade de pointes, and cardiovascular mortality, which is increased by the addition of azithromycin. Several cases of cardiac arrest have been reported.
16 April 2020

Covid-19 and hydroxychloroquine (Plaquenil°): new data show no evidence of efficacy

 NEWS UPDATE  The results of a new randomised comparative but non-blinded trial of high-dose hydroxychloroquine (Plaquenil°) versus standard care in 150 patients hospitalised for covid-19 have been published. The only notable difference between the groups was the high incidence of adverse effects in the group treated with hydroxychloroquine. The results of other studies (non-randomised and providing only low-quality evidence) show no evidence that hydroxychloroquine has efficacy against covid-19.
16 April 2020

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90